Blog
RSS FeedPosted by Michael Wonder on 05 Aug 2019
Dacomitinib in advanced lung cancer: variety of disadvantages lifts survival advantage
1 August 2019 - Prolonged survival is sometimes accompanied by severe side effects, symptom and quality of life deterioration ...
Posted by Michael Wonder on 31 Jul 2019
Ezetimibe reduces the risk of heart attacks and strokes
26 July 2019 - Added to existing statin therapy, ezetimibe is preventative in patients with CHD and acute coronary syndrome. ...
Posted by Michael Wonder on 13 Jul 2019
Early benefit assessment reveals weaknesses in the development of new drugs
11 July 2019 - Analysis of 216 AMNOG assessments in the BMJ / Proposals for more targeted drug development ...
Posted by Michael Wonder on 20 May 2019
Europe responding to gene therapy challenge, but picture remains fragmented
20 May 2019 - Germany, Italy and England using outcomes-based deals. ...
Posted by Michael Wonder on 15 May 2019
Nivolumab and ipilimumab: drug combination has added benefit in advanced renal cell carcinoma
15 May 2019 - There are no serious disadvantages in terms of overall survival. ...
Posted by Michael Wonder on 02 May 2019
Apalutamide in prostate cancer: indication of significant added benefit
2 May 2019 - Study shows significant slowing of symptomatic progression. ...
Posted by Michael Wonder on 16 Apr 2019
Ribociclib in advanced breast cancer: survival benefits, but also severe side effects
15 April 2019 - In the overall view, an added benefit is not proven. ...
Posted by Michael Wonder on 26 Mar 2019
Numerous G-BA decisions on new medicines - five active substances with considerable added value
22 March 2019 - On Friday in Berlin, the Federal Joint Committee (G-BA) made numerous decisions on the extent of the ...
Posted by Michael Wonder on 03 Feb 2019
Erenumab in migraine: indication of a significant added benefit for certain patients
2 February 2019 - As a prophylaxis successful when other drug therapies are exhausted. ...
Posted by Michael Wonder on 15 Jan 2019
Progressive squamous cell carcinoma of the head and neck: pembrolizumab prolongs survival
15 January 2019 - Only a few study participants were treated in compliance with the approval, therefore the extent of ...
Posted by Michael Wonder on 08 Dec 2018
AMNOG as a learning system: new study on ingenol mebutate in actinic keratosis shows added benefit
3 December 2018 - Advantage over diclofenac in complete clearance of visible lesions / unclear sustainability of treatment effect ...
Posted by Michael Wonder on 01 Oct 2018
Pertuzumab in early breast cancer: no proof of an additional benefit despite exemplary surrogate validation
1 October 2018 - Effect on disease-free survival too small to conclude on overall survival. ...
Posted by Michael Wonder on 02 Jul 2018
Haemophilia A and sialorrhoea: contemporary comparative therapies not implemented so added benefit not proven
2 July 2018 - Of the four dossier evaluations published by the IQWiG on 2 July, two have a striking similarity ...
Posted by Michael Wonder on 14 Jun 2018
Effect of cross-over in oncology clinical trials on evidence levels in early benefit assessment in Germany
13 June 2018 - In oncology clinical trials, cross-over is used frequently but may lead to uncertainties regarding treatment effects. ...
Posted by Michael Wonder on 13 Jun 2018
Janssen’s Tremfya (guselkumab) receives its first two positive Health Technology Assessments in Europe
13 June 2018 - The United Kingdom’s NICE publishes positive guidance for the first selective interleukin 23 inhibitor to treat moderate ...